Motohiro Izumi

Wakayama, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Targeting drug-tolerant persister cells: Let's bring on the TROPs!

Targeting drug-tolerant persister cells: Let's bring on the TROPs!

Journal: Cancer cell
Published: May 22, 2026

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.

Journal: Cancer treatment and research communications
Published: August 21, 2025

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 08, 2024

Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer.

Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer.

Journal: Cell death & disease
Published: March 27, 2024

RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.

RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.

Journal: Anticancer research
Published: July 21, 2023

Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer.

Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer.

Journal: Cancer chemotherapy and pharmacology
Published: May 31, 2023

Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.

Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.

Journal: Anticancer research
Published: February 20, 2023

Vimentin expression correlates with immune checkpoint inhibitor efficacy in non-small cell lung cancer.

Vimentin expression correlates with immune checkpoint inhibitor efficacy in non-small cell lung cancer.

Journal: Cancer
Published: August 18, 2022

SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.

SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.

Journal: Translational lung cancer research
Published: July 01, 2022

Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.

Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.

Journal: Cancer science
Published: May 12, 2022

Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.

Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.

Journal: Thoracic cancer
Published: May 09, 2022

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.

A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.

Journal: Respiratory medicine case reports
Published: November 09, 2021
Showing 1-12 of 19

Last Updated: 09/26/2026